8-K: Current report filing
Published on October 28, 2024
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 24, 2024
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (609 )
322-1602
Acasti Pharma Inc.
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.03. |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
|
On October 24, 2024, Grace Therapeutics, Inc. (the “Company”) filed a certificate of amendment (the “Certificate of Amendment”) to its Certificate of
Incorporation with the Secretary of State of the State of Delaware solely to change the Company’s name from “Acasti Pharma Inc.” to “Grace Therapeutics, Inc.” The name change became effective on October 28, 2024. A copy of the Certificate of
Amendment is attached as Exhibit 3.1 hereto and incorporated herein by reference.
In connection with the name change, the Company’s Board of Directors amended the Company’s Bylaws (the “Bylaws”) to reflect the Company’s name change,
also effective October 28, 2024. No other changes were made to the Bylaws. A copy of the Bylaws reflecting this amendment is attached as Exhibit 3.2 hereto and incorporated herein by reference.
The Company’s common stock previously traded on the Nasdaq Stock Market under the ticker symbol “ACST” and, effective as of October 28, 2024, is trading
on the Nasdaq Stock Market under the new ticker symbol “GRCE”.
The name change does not affect the rights of the Company’s security holders, and the CUSIP number for the Company’s common stock will continue to be
00439U104.
| Item 9.01. |
Financial Statements and Exhibits.
|
(d) Exhibits
|
Exhibit
|
Description
|
|
|
Certificate of Amendment to the Certificate of Incorporation of Grace Therapeutics, Inc.
|
||
|
Bylaws of Grace Therapeutics, Inc.
|
||
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
GRACE THERAPEUTICS, INC.
|
||
|
October 28, 2024
|
By:
|
/s/ Prashant
Kohli
|
|
Name:
|
Prashant Kohli
|
|
|
Title:
|
Chief Executive Officer
|
|